Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $20.90M | $24.56M |
| Net Income | -$16.29M | -$12.32M |
| EPS Diluted | -$0.38 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
